Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 17Pancreatic Neoplasms 11Carcinoma, Hepatocellular 10Colonic Neoplasms 7Rectal Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Cholangiocarcinoma 4Breast Neoplasms 4Prostatic Neoplasms 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Hematologic Neoplasms 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Thrombocytosis 1Somatostatinoma 1Sarcoma 1Resectable Intrahepatic Cholangiocarcinoma 1Recurrence 1

Interventions

Gemcitabine 113Cisplatin 77Oxaliplatin 46pembrolizumab 35Fluorouracil 33Capecitabine 31durvalumab 27Leucovorin 27lenvatinib 26Magnetic Resonance Spectroscopy 15Irinotecan 14Drug Therapy 13Biopsy 13Nivolumab 12Albumin-Bound Paclitaxel 12tislelizumab 11Specimen Handling 11Radiofrequency Ablation 11130-nm albumin-bound paclitaxel 11pemigatinib 10apatinib 10Taxes 10Radiotherapy 10Floxuridine 10Folfox protocol 9Bevacizumab 9S 1 (combination) 8Platinum 8Photochemotherapy 8Liver Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Disulfides × Gastrointestinal × Clear all
NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Not yet recruiting
46 enrolled
Gastrointestinal

Pancreatic Neoplasms, Cholangiocarcinoma

NCT06058663 2026-05-13

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Recruiting
16 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic

Phase 1/2 Recruiting
85 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT04941287 2025-05-23

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
57 enrolled 13 charts
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡